XF-73

XF-73 (Exeporﬁnium chloride) is an experimental drug candidate. It is an anti-microbial which works via weakening bacteria cell walls. It is a potential treatment for methicillin-resistant Staphylococcus aureus (MRSA) and possibly Clostridium difficile. It is being developed by Destiny Pharma Ltd.

It has completed a phase I clinical trial for nasal decolonisation of MRSA—being tested against 5 bacterial strains. It seems unlikely to cause MRSA to develop resistance to it.

Structurally it is a dicationic porphyrin.